MAPT and Alzheimer disease: Elevated concentrations of P-tau181 were previously associated with rapid cognitive decline in AD [24], and more recently the P-tau217 residue has started to be evaluated alongside P-tau181 as an indicator of amyloid and tau pathology in clinical settings [27].